Effects of candesartan and propranolol combination therapy versus propranolol monotherapy in reducing portal hypertension
2
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
Background/Aims: Angiotensin receptor blockers (ARBs) inhibit activated hepatic stellate cell contraction and are thought to reduce the dynamic portion of intrahepatic resistance. This study compared the effects of combined treatment using the ARB candesartan and propranolol versus propranolol monotherapy on portal pressure in patients with cirrhosis in a prospective, randomized controlled trial. Methods: Between January 2008 and July 2009, 53 cirrhotic patients with clinically significant portal hypertension were randomized to receive either candesartan and propranolol combination therapy (26 patients) or propranolol monotherapy (27 patients). Before and 3 months after the administration of the planned medication, the hepatic venous pressure gradient (HVPG) was assessed in both groups. The dose of propranolol was subsequently increased from 20 mg bid until the target heart rate was reached, and the candesartan dose was fixed at 8 mg qd. The primary endpoint was the HVPG response rate; patients with an HVPG reduction of >20% of the baseline value or to <12 mmHg were defined as responders. Results: The mean portal pressure declined significantly in both groups, from 16 mmHg (range, 12.28 mmHg) to 13.5 mmHg (range, 6.20 mmHg) in the combination group (P<0.05), and from 17 mmHg (range, 12.27 mmHg) to 14 mmHg (range, 7.25 mmHg) in the propranolol monotherapy group (P<0.05). However, the medication-induced pressure reduction did not differ significantly between the two groups [3.5 mmHg (range, -3.11 mmHg) vs. 3 mmHg (range, -8.10 mmHg), P=0.674]. The response rate (55.6% vs. 61.5%, P=0.435) and the reductions in mean blood pressure or heart rate also did not differ significantly between the combination and monotherapy groups. Conclusions: The addition of candesartan (an ARB) to propranolol confers no benefit relative to classical propranolol monotherapy for the treatment of portal hypertension, and is thus not recommended.
Abstract
Background/Aims: Angiotensin receptor blockers (ARBs) inhibit activated hepatic stellate cell contraction and are thought to reduce the dynamic portion of intrahepatic resistance. This study compared the effects of combined treatment using the ARB candesartan and propranolol versus propranolol monotherapy on portal pressure in patients with cirrhosis in a prospective, randomized controlled trial. Methods: Between January 2008 and July 2009, 53 cirrhotic patients with clinically significant portal hypertension were randomized to receive either candesartan and propranolol combination therapy (26 patients) or propranolol monotherapy (27 patients). Before and 3 months after the administration of the planned medication, the hepatic venous pressure gradient (HVPG) was assessed in both groups. The dose of propranolol was subsequently increased from 20 mg bid until the target heart rate was reached, and the candesartan dose was fixed at 8 mg qd. The primary endpoint was the HVPG response rate; patients with an HVPG reduction of >20% of the baseline value or to <12 mmHg were defined as responders. Results: The mean portal pressure declined significantly in both groups, from 16 mmHg (range, 12.28 mmHg) to 13.5 mmHg (range, 6.20 mmHg) in the combination group (P<0.05), and from 17 mmHg (range, 12.27 mmHg) to 14 mmHg (range, 7.25 mmHg) in the propranolol monotherapy group (P<0.05). However, the medication-induced pressure reduction did not differ significantly between the two groups [3.5 mmHg (range, -3.11 mmHg) vs. 3 mmHg (range, -8.10 mmHg), P=0.674]. The response rate (55.6% vs. 61.5%, P=0.435) and the reductions in mean blood pressure or heart rate also did not differ significantly between the combination and monotherapy groups. Conclusions: The addition of candesartan (an ARB) to propranolol confers no benefit relative to classical propranolol monotherapy for the treatment of portal hypertension, and is thus not recommended.
참고문헌 (31)
- Kim MY, "Hepatic venous pressure gradient can predict the development of hepatocellular carcinoma and hyponatremia in decompensated alcoholic cirrhosis", Eur J Gastroenterol Hepatol, 21, pp.1241~1246 (2009)
- Kim MY, "Histological subclassification of cirrhosis using the Laennec fibrosis scoring system correlates with clinical stage and grade of portal hypertension", J Hepatol, 55, pp.1004~1009 (2011)
- Kim MY, "Hepatic vein arrival time as assessed by contrast-enhanced ultrasonography is useful for the assessment of portal hypertension in compensated cirrhosis", Hepatology, 56, pp.1053~1062 (2012)
- D’Amico G, "Multicenter Italian Group. End-ofthe-century reappraisal of the 6-week outcome of upper gastrointestinal bleeding in cirrhosis. A prospective study", J Hepatol, 30, pp.86~ (1999)
- 홍원기, "The usefulness of non-invasive liver stiffness measurements in predicting clinically significant portal hypertension in cirrhotic patients: Korean data", Clinical and Molecular Hepatology, 19(4), pp.370~375 (2013), 대한간학회
- D’Amico G, "Diagnosis of portal hypertension: how and when, Portal Hypertension III", Proceedings of the Third Baveno International Consensus Workshop on Definitions, Methodology and Therapeutic Strategies, pp.36~64 (2001), Blackwell Science
- 김문영, "Clinical features and outcomes of gastric variceal bleeding: retrospective Korean multicenter data", Clinical and Molecular Hepatology, 19(1), pp.36~44 (2013), 대한간학회[DOI]
- Feu F1, "Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis", Lancet, 346, pp.1056~1059 (1995)
- Ballet F, "Differential response of normal and cirrhotic liver to vasoactive agents. A study in the isolated perfused rat liver", J Pharmacol Exp Ther, 244, pp.283~289 (1988)
- Kim MY, "Beneficial effects of candesartan, an angiotensin-blocking agent, on compensated alcoholic liver fibrosis - a randomized open-label controlled study", Liver Int, 32, pp.977~987 (2012)
- Bataller R, "Angiotensin II induces contraction and proliferation of human hepatic stellate cells", Gastroenterology, 118, pp.1149~1156 (2000)
- Friedman SL., "Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury", J Biol Chem, 275, pp.2247~2250 (2000)
- Turnes J, "Pharmacological reduction of portal pressure and longterm risk of first variceal bleeding in patients with cirrhosis", Am J Gastroenterol, 101, pp.506~512 (2006)
- Schneider AW, "Effect of losartan, an angiotensin II receptor antagonist, on portal pressure in cirrhosis", Hepatology, 29, pp.334~339 (1999)
- De BK, "Portal pressure response to losartan compared with propranolol in patients with cirrhosis", Am J Gastroenterol, 98, pp.1371~1376 (2003)
- Yokohama S, "Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis", Hepatology, 40, pp.1222~1225 (2004)
- Schepke M, "Comparison of portal vein velocity and the hepatic venous pressure gradient in assessing the acute portal hemodynamic response to propranolol in patients with cirrhosis", Am J Gastroenterol, 95, pp.2905~2909 (2000)
- Baik SK, "Acute hemodynamic effects of octreotide and terlipressin in patients with cirrhosis:a randomized comparison", Am J Gastroenterol, 100, pp.631~635 (2005)
- Baik SK, "Recent variceal bleeding: Doppler US hepatic vein waveform in assessment of severity of portal hypertension and vasoactive drug response", Radiology, 240, pp.574~580 (2006)
- Kim MY, "Invasive and non-invasive diagnosis of cirrhosis and portal hypertension", World J Gastroenterol, 20, pp.4300~4315 (2014)
- Bosch J, "Complications of cirrhosis. I. Portal hypertension", J Hepatol, 32, pp.141~156 (2000)
- Groszmann RJ, "Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage", Gastroenterology, 99, pp.1401~1407 (1990)
- Ki Tae Suk, "Effect of Propranolol on Portal Pressure and Systemic Hemodynamics in Patients with Liver Cirrhosis and Portal Hypertension: A Prospective Study", Gut and Liver, 1(2), pp.159~164 (2007), 거트앤리버 발행위원회
- Groszmann RJ, "Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis", N Engl J Med, 353, pp.2254~2261 (2005)
- Rockey D., "The cellular pathogenesis of portal hypertension: stellate cell contractility, endothelin, and nitric oxide", Hepatology, 25, pp.2~5 (1997)
- Schepke M, "Hemodynamic effects of the angiotensin II receptor antagonist irbesartan in patients with cirrhosis and portal hypertension", Gastroenterology, 121, pp.389~395 (2001)
- González-Abraldes J, "Randomized comparison of long-term losartan versus propranolol in lowering portal pressure in cirrhosis", Gastroenterology, 121, pp.382~388 (2001)
- Kim MY, "Angiotensin receptor blockers are superior to angiotensin-converting enzyme inhibitors in the suppression of hepatic fibrosis in a bile duct-ligated rat model", J Gastroenterol, 43, pp.889~896 (2008)
- McClellan KJ, "Candesartan cilexetil. A review of its use in essential hypertension", Drugs, 56, pp.847~869 (1998)
- Ojima M, "Candesartan (CV-11974) dissociates slowly from the angiotensin AT1 receptor", Eur J Pharmacol, 319, pp.137~146 (1997)
- Burnier M, "Angiotensin II receptor antagonists", Lancet, 355, pp.637~645 (2000)